Although a clinical advantage was observed in BRAF-mutant CRC patients treated with BRAF, EGFR and MEK inhibitors, the extent of the clinical responses was time-limited, suggesting the urgency of discovering molecular mechanisms driving CRC acquired resistance [43]. The gene discussed is MAP2K7; the disease is colorectal carcinoma.